Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2019-02-06 Major Shareholding Noti…
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification
2019-02-06 English
FORM 4 SUBMISSION
Director's Dealing
2018-12-06 English
FORM 3 SUBMISSION
Director's Dealing
2018-12-06 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 6, 2018, reporting the appointment of a new director to the Board of Organovo Holdings, Inc. It details the increase in board size, the appointment of Dr. David Shapiro as a Class I Director, his background, compensation, and indemnification agreement. The key section is Item 5.02, which specifically relates to the departure or appointment of directors or certain officers. There is no financial data or earnings information, nor is this a report or announcement of financial results. The document is clearly an announcement of changes in the company's board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (9081 characters) supports that this is a full filing rather than a brief announcement or certification. Confidence is high given the explicit content and form type.
2018-12-06 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 27, 2018, reporting the departure of a named executive officer, Dr. Sharon Presnell, from her positions as Chief Scientific Officer and President of a subsidiary. The key content is about management changes, specifically the resignation of a senior officer. There are no financial statements or detailed financial data, so it is not an annual or interim report. The document fits the category of announcements related to changes in the company's board or senior management. Therefore, the appropriate classification is 'Board/Management Information' (MANG). The document length is 3057 characters, which is consistent with a typical 8-K management change filing. Confidence is high due to the clear and explicit content about management departure.
2018-11-27 English
FORM 4 SUBMISSION
Director's Dealing
2018-11-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.